These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

132 related articles for article (PubMed ID: 22526827)

  • 1. A case of aseptic abscesses syndrome treated with corticosteroids and TNF-alpha blockade.
    Ito T; Sato N; Yamazaki H; Koike T; Emura I; Saeki T
    Mod Rheumatol; 2013 Jan; 23(1):195-9. PubMed ID: 22526827
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Efficacy of Il-1β blockade in refractory aseptic abscesses syndrome.
    Bardy A; Guettrot-Imbert G; Aumaître O; André MF
    Mod Rheumatol; 2014 Jan; 24(1):217-9. PubMed ID: 24261782
    [No Abstract]   [Full Text] [Related]  

  • 3. Pyoderma gangrenosum and tumor necrosis factor α agents.
    Rallis E; Koumantaki-Mathioudaki E; Tsiatoura A; Stavropoulos P; Katsambas A
    Cutis; 2013 Oct; 92(4):E1-2. PubMed ID: 24195097
    [No Abstract]   [Full Text] [Related]  

  • 4. The emerging use of TNF-alpha inhibitors in orbital inflammatory disease.
    Kapadia MK; Rubin PA
    Int Ophthalmol Clin; 2006; 46(2):165-81. PubMed ID: 16770161
    [No Abstract]   [Full Text] [Related]  

  • 5. Treatment of thalidomide resistant pyoderma gangrenosum with etenercept.
    Guedes R; Moreira A; Menezes N; Baptista A; Varela P
    Acta Dermatovenerol Croat; 2012; 20(3):175-80. PubMed ID: 23069303
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Development of Crohn disease during anti-TNF-alpha therapy in a child with juvenile idiopathic arthritis.
    Ruemmele FM; Prieur AM; Talbotec C; Goulet O; Schmitz J
    J Pediatr Gastroenterol Nutr; 2004 Aug; 39(2):203-6. PubMed ID: 15269630
    [No Abstract]   [Full Text] [Related]  

  • 7. A case of arthritis and vasculitis associated with the refractory anemia with excess of blasts syndrome resistant to glucocorticoid treatment that responded favorably to TNF-alpha blockade.
    Pipitone N; Masini L; Salvarani C
    Clin Exp Rheumatol; 2006; 24(2 Suppl 41):S31-4. PubMed ID: 16859593
    [No Abstract]   [Full Text] [Related]  

  • 8. Pyoderma gangrenosum, acne conglobata, suppurative hidradenitis, and axial spondyloarthritis: efficacy of anti-tumor necrosis factor α therapy.
    Bruzzese V
    J Clin Rheumatol; 2012 Dec; 18(8):413-5. PubMed ID: 23188209
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Tumor necrosis factor alpha inhibitors for the treatment of dermatologic diseases.
    Trent JT; Kerdel FA
    Dermatol Nurs; 2005 Apr; 17(2):97-107. PubMed ID: 15916184
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Abnormal production of tumor necrosis factor (TNF) -- alpha and clinical efficacy of the TNF inhibitor etanercept in a patient with PAPA syndrome [corrected].
    Cortis E; De Benedetti F; Insalaco A; Cioschi S; Muratori F; D'Urbano LE; Ugazio AG
    J Pediatr; 2004 Dec; 145(6):851-5. PubMed ID: 15580218
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Differential effectiveness of etanercept and infliximab in the treatment of ocular inflammation.
    Galor A; Perez VL; Hammel JP; Lowder CY
    Ophthalmology; 2006 Dec; 113(12):2317-23. PubMed ID: 16996615
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pyoderma gangrenosum treated with anti-TNF alpha therapy (etanercept).
    Pastor N; Betlloch I; Pascual JC; Blanes M; Bañuls J; Silvestre JF
    Clin Exp Dermatol; 2006 Jan; 31(1):152-3. PubMed ID: 16309525
    [No Abstract]   [Full Text] [Related]  

  • 13. Diverse effects of infliximab and etanercept on T lymphocytes.
    Sieper J; Van Den Brande J
    Semin Arthritis Rheum; 2005 Apr; 34(5 Suppl1):23-7. PubMed ID: 15852251
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Treatment of pyoderma gangrenosum with etanercept.
    McGowan JW; Johnson CA; Lynn A
    J Drugs Dermatol; 2004; 3(4):441-4. PubMed ID: 15303791
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Treatment of pyoderma gangrenosum with the anti-TNFalpha drug - Etanercept.
    Rogge FJ; Pacifico M; Kang N
    J Plast Reconstr Aesthet Surg; 2008; 61(4):431-3. PubMed ID: 18358433
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The role of anti-tumor necrosis factor-alpha therapy in Pyoderma gangrenosum associated with inflammatory bowel disease.
    Reguiaï Z; Grange F
    Am J Clin Dermatol; 2007; 8(2):67-77. PubMed ID: 17428111
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Anti-TNF alpha agents in vasculitis].
    Solans Laqué R; Bosch Gil JA
    Med Clin (Barc); 2008 Feb; 130(3):93-4. PubMed ID: 18261379
    [No Abstract]   [Full Text] [Related]  

  • 18. Emerging role of anti-tumor necrosis factor therapy in rheumatic diseases.
    Kalden JR
    Arthritis Res; 2002; 4 Suppl 2(Suppl 2):S34-40. PubMed ID: 12110156
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Aseptic abscesses: a study of 30 patients with or without inflammatory bowel disease and review of the literature.
    André MFJ; Piette JC; Kémény JL; Ninet J; Jego P; Delèvaux I; Wechsler B; Weiller PJ; Francès C; Blétry O; Wismans PJ; Rousset H; Colombel JF; Aumaître O;
    Medicine (Baltimore); 2007 May; 86(3):145-161. PubMed ID: 17505254
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The use of etanercept in the treatment of peristomal pyoderma gangrenosum.
    Kim FS; Pandya AG
    Clin Exp Dermatol; 2012 Jun; 37(4):442-3. PubMed ID: 22582915
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.